Entinostat addition fails to improve aromatase inhibitor-resistant breast cancer outcomes

Roisin Connolly discusses the next steps following the negative results of the phase 3 ECOG-ACRIN E2112 trial of the HDAC inhibitor entinostat in combination with endocrine therapy in aromatase inhibitor-resistant patients with advanced breast cancer (2:43).